Public Sector Pension Investment Board Has $14.04 Million Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Key Points

• Public Sector Pension Investment Board increased its stake in DexCom, Inc. by 2.8% in Q1, now holding over 205,000 shares valued at approximately $14 million.
• Other institutional investors, such as Vanguard Group and Jennison Associates, also raised their positions significantly, with a combined ownership of nearly 97.75% of DexCom's stock.
• Analyst ratings are predominantly positive, with four analysts holding a "hold," sixteen giving a "buy," and three a "strong buy" rating, along with an average price target of approximately $99.89.

Public Sector Pension Investment Board lifted its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 2.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 205,537 shares of the medical device company's stock after purchasing an additional 5,613 shares during the quarter. Public Sector Pension Investment Board owned about 0.05% of DexCom worth $14,036,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in DXCM. Nia Impact Advisors LLC raised its position in shares of DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after acquiring an additional 140 shares in the last quarter. Wedbush Securities Inc. increased its position in DexCom by 1.2% during the first quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company's stock worth $899,000 after buying an additional 157 shares in the last quarter. Argonautica Private Wealth Management Inc. increased its position in DexCom by 3.2% during the first quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company's stock worth $407,000 after buying an additional 182 shares in the last quarter. Personal CFO Solutions LLC boosted its holdings in shares of DexCom by 7.3% during the first quarter. Personal CFO Solutions LLC now owns 3,446 shares of the medical device company's stock worth $235,000 after purchasing an additional 234 shares during the last quarter. Finally, SeaCrest Wealth Management LLC increased its stake in DexCom by 5.6% in the first quarter. SeaCrest Wealth Management LLC now owns 4,696 shares of the medical device company's stock valued at $321,000 after purchasing an additional 249 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 500 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $41,400.00. Following the sale, the executive vice president owned 95,102 shares of the company's stock, valued at $7,874,445.60. The trade was a 0.52% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Nicholas Augustinos sold 3,672 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the sale, the director directly owned 33,411 shares in the company, valued at $2,766,430.80. This trade represents a 9.90% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,656 shares of company stock worth $2,412,191. Corporate insiders own 0.32% of the company's stock.

DexCom Stock Performance

NASDAQ:DXCM remained flat at $79.96 during trading hours on Thursday. 2,234,312 shares of the company traded hands, compared to its average volume of 3,950,381. The stock's fifty day moving average price is $83.17 and its 200-day moving average price is $80.14. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The company has a market capitalization of $31.36 billion, a PE ratio of 55.53, a price-to-earnings-growth ratio of 1.68 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the previous year, the firm posted $0.43 EPS. The business's revenue was up 15.2% compared to the same quarter last year. Equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on DXCM shares. Barclays raised their price target on shares of DexCom from $93.00 to $98.00 and gave the company an "equal weight" rating in a report on Wednesday, July 30th. Robert W. Baird lowered their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Citigroup reissued a "buy" rating and issued a $102.00 price objective (up from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Canaccord Genuity Group reissued a "buy" rating and issued a $106.00 price objective on shares of DexCom in a report on Friday, August 1st. Finally, Truist Financial initiated coverage on DexCom in a report on Monday, June 16th. They issued a "buy" rating and a $102.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $99.89.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.